# Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.

> **NCT00325416** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 177 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** melphalan
- **DRUG:** topotecan (TPT)
- **PROCEDURE:** Autologous Stem Cell Rescue

## Key facts

- **NCT ID:** NCT00325416
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11-19
- **Primary completion:** 2013-07-15
- **Final completion:** 2018-01-30
- **Target enrollment:** 177 (ACTUAL)
- **Last updated:** 2018-03-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00325416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00325416, "Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00325416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*